Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 5/20 | 0.43 |
| ▸ | CTSL | P07711 | 5/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 6/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KIT | P10721 | 1/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7248143 | 0.90 | HCRTR2 (0.40) | CTSVCTSLHCRTR2MEN1KMT2A | |
| SCHEMBL7245164 | 0.89 | SMN1; SMN2 (0.40) | CTSVCTSLHCRTR2MAPTMEN1 | |
| SCHEMBL7243329 | 0.88 | CTSV (0.43) | CTSVCTSLMAPTMEN1KMT2A | |
| SCHEMBL7245109 | 0.88 | MCHR1 (0.39) | CTSVCTSLHCRTR2MAPTMEN1 | |
| SCHEMBL7250691 | 0.87 | CTSV (0.46) | CTSVCTSLHCRTR2MEN1KMT2A | |
| SCHEMBL7251107 | 0.86 | HCRTR2 (0.44) | HCRTR2MAPTMEN1KMT2AABCB1 | |
| SCHEMBL7242898 | 0.86 | ABCB1 (0.42) | CTSVCTSLHCRTR2MAPTMEN1 | |
| SCHEMBL7250081 | 0.85 | CTSV (0.47) | CTSVCTSLHCRTR2MAPTMEN1 | |
| SCHEMBL6742105 | 0.84 | CTSV (0.43) | CTSVCTSLHCRTR2MAPTMEN1 | |
| SCHEMBL6742341 | 0.84 | CTSV (0.43) | CTSVCTSLHCRTR2MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030045727-A1 | Process for preparing optically active secondary alcohols having nitrogenous or oxygenic functional groups | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2003-03-06 | — | — | US | disclosed |
| EP-1254885-A1 | PROCESS FOR PREPARING OPTICALLY ACTIVE SECONDARY ALCOHOLS HAVING NITROGENOUS OR OXYGENIC FUNCTIONAL GROUPS | Asahi Kasei Kabushiki Kaisha (JP) | 2002-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045727-A1 | Process for preparing optically active secondary alcohols having nitrogenous or oxygenic functional groups | ADH1A, ADH5, ADH1C | CTSV 4705/4885CTSL 4734/4885HCRTR2 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.